Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

Repisalud
Publication Tesis doctoral (DoctoralThesis)

Histone Deacetylase 6 at Crossroads of Invection and Innate Immunity

  • Moreno-Gonzalo, Olga
Recent evidence on Histone deacetyase 6 (HDAC6) function underlines its role as a key protein in the innate immune response to viral infection. However, whether HDAC6 regulates innate immunity during bacterial infection remains unexplored. To assess the role of HDAC6 in the regulation of defence mechanisms against intracellular bacteria, we used the Listeria monocytogenes (Lm) infection model. Here we describe that in the absence of HDAC6 Granulocyte/Macrophage colony stimulating factorderived dendritic cells (GM‐CSF DCs) display higher intracellular bacterial titres than their wild type (wt) counterparts. The impaired bacterial clearance appears to be caused by a defect in autophagy. This correlates with an increase in the accumulation of the autophagy marker p62 in Hdac6‐/‐ DCs, due to a defective phagosome‐lysosome fusion. We also identify higher levels of acetylated cortactin colocalizing with intracellular bacteria in Hdac6‐/‐ DCs compared to wt, suggesting that this Posttranslational modification (PTM) in cortactin could delay the phagosome‐lysosome fusion. Additionally, a lower expression of interferon‐related genes and pro‐inflammatory cytokines is detected in Hdac6‐/‐ DCs after Lm infection. This observation is in accordance with lower nitrite production and inducible nitric oxide synthase (iNOS) induction during bacterial infection in Hdac6‐/DCs. Likewise, phosphorylation of Mitogen‐activated protein kinase (MAPK) and mammalian target of rapamycin (mTOR) signalling pathways is reduced in Hdac6‐/‐ DCs in response to Lm, suggesting an altered Toll‐like receptor response to Lm and various TLR agonists is detected in both Hdac6‐/‐ GM‐CSF‐derived and FMS‐like tyrosine kinase 3 (FLT3L)‐derived dendritic cells. Interestingly, our data reveal the molecular association of HDAC6 with the TLR‐adaptor protein Myeloid differentiation primary response gene 88 (MyD88), and how the absence of HDAC6 seems to diminish Nuclear factor κB (NF‐κB) induction after TLR stimuli. Moreover, Hdac6‐/‐ mice display low serum levels of the inflammatory cytokine IL‐6 and correspondingly an increased survival to a systemic infection with a lethal dose of Lm. These data underline the important function of HDAC6 in DCs, not only in the control of bacterial burden through degradation by autophagy, but also in the proper activation of TLR signalling. These results thus underscore an important regulatory role for HDAC6 in almost every step of DC functions against intracellular bacterial infection, highlithing HDAC6 as a new player of innate immune responses. (TLR) signalling. A defective pro‐inflammatory cytokine production in
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Diagnosis of autosomal dominant polycystic kidney disease using efficient PKD1 and PKD2 targeted next-generation sequencing

  • Trujillano, Daniel
  • Bullich Vilanova, Gemma|||0000-0002-0737-4422
  • Ossowski, Stephan|||0000-0002-7416-9568
  • Ballarín Castan, José Aurelio|||0000-0002-4556-8164
  • Torra Balcells, Roser|||0000-0001-8714-2332
  • Estivill, Xavier|||0000-0002-0723-2256
  • Ars, Elisabet|||0000-0002-4118-4358
Molecular diagnostics of autosomal dominant polycystic kidney disease (ADPKD) relies on mutation screening of PKD1 and PKD2, which is complicated by extensive allelic heterogeneity and the presence of six highly homologous sequences of PKD1. To date, specific sequencing of PKD1 requires laborious long-range amplifications. The high cost and long turnaround time of PKD1 and PKD2 mutation analysis using conventional techniques limits its widespread application in clinical settings. We performed targeted next-generation sequencing (NGS) of PKD1 and PKD2. Pooled barcoded DNA patient libraries were enriched by in-solution hybridization with PKD1 and PKD2 capture probes. Bioinformatics analysis was performed using an in-house developed pipeline. We validated the assay in a cohort of 36 patients with previously known PKD1 and PKD2 mutations and five control individuals. Then, we used the same assay and bioinformatics analysis in a discovery cohort of 12 uncharacterized patients. We detected 35 out of 36 known definitely, highly likely, and likely pathogenic mutations in the validation cohort, including two large deletions. In the discovery cohort, we detected 11 different pathogenic mutations in 10 out of 12 patients. This study demonstrates that laborious long-range PCRs of the repeated PKD1 region can be avoided by in-solution enrichment of PKD1 and PKD2 and NGS. This strategy significantly reduces the cost and time for simultaneous PKD1 and PKD2 sequence analysis, facilitating routine genetic diagnostics of ADPKD.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Targeted next-generation sequencing in steroid-resistant nephrotic syndrome, mutations in multiple glomerular genes may influence disease severity

  • Bullich Vilanova, Gemma|||0000-0002-0737-4422
  • Trujillano, Daniel
  • Santín, Sheila
  • Ossowski, Stephan|||0000-0002-7416-9568
  • Mendizábal, Santiago
  • Fraga Rodriguez, Gloria Maria|||0000-0002-7682-1396
  • Madrid, Alvaro
  • Ariceta Iraola, Gema|||0000-0003-1763-1098
  • Ballarín Castan, José Aurelio|||0000-0002-4556-8164
  • Torra Balcells, Roser|||0000-0001-8714-2332
  • Estivill, Xavier|||0000-0002-0723-2256
  • Ars, Elisabet|||0000-0002-4118-4358
Genetic diagnosis of steroid-resistant nephrotic syndrome (SRNS) using Sanger sequencing is complicated by the high genetic heterogeneity and phenotypic variability of this disease. We aimed to improve the genetic diagnosis of SRNS by simultaneously sequencing 26 glomerular genes using massive parallel sequencing and to study whether mutations in multiple genes increase disease severity. High-throughput mutation analysis was performed in 50 SRNS and/or focal segmental glomerulosclerosis (FSGS) patients, a validation cohort of 25 patients with known pathogenic mutations, and a discovery cohort of 25 uncharacterized patients with probable genetic etiology. In the validation cohort, we identified the 42 previously known pathogenic mutations across NPHS1, NPHS2, WT1, TRPC6, and INF2 genes. In the discovery cohort, disease-causing mutations in SRNS/FSGS genes were found in nine patients. We detected three patients with mutations in an SRNS/FSGS gene and COL4A3. Two of them were familial cases and presented a more severe phenotype than family members with mutation in only one gene. In conclusion, our results show that massive parallel sequencing is feasible and robust for genetic diagnosis of SRNS/FSGS. Our results indicate that patients carrying mutations in an SRNS/FSGS gene and also in COL4A3 gene have increased disease severity.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Incidence of myeloid neoplasms in Spain (2002-2013), a population-based study of the Spanish network of cancer registries

  • Solans, Marta|||0000-0002-2397-0435
  • Sanvisens, Arantza|||0000-0001-6269-5491
  • Ameijide, Alberto
  • Merino, Susana
  • Rojas, Dolores
  • Alemán, Araceli
  • Banqueri, Emilia
  • Chico, Matilde
  • Marcos, Ana Isabel
  • de Castro, Visitación
  • Gil, Leire
  • López de Munain, Arantza|||0000-0001-6820-9124
  • Puigdemont, Montse|||0000-0001-9961-3699
  • Sánchez Pérez, María José|||0000-0003-4817-0757
  • Perucha, Josefina
  • Ruiz-Armengol, Patricia
  • Chirlaque López, María Dolores
  • Guevara, Marcela|||0000-0001-9242-6364
  • Carulla, Marià
  • Marcos-Gragera, Rafael|||0000-0001-9824-3657
Comprehensive population-based data on myeloid neoplasms (MNs) are limited, mainly because some subtypes were not recognized as hematological cancers prior to the WHO publication in 2001, and others are too rare to allow robust estimates within regional studies. Herein, we provide incidence data of the whole spectrum of MNs in Spain during 2002-2013 using harmonized data from 13 population-based cancer registries. Cases (n = 17,522) were grouped following the HAEMACARE groupings and 2013-European standardized incidence rates (ASR), incidence trends, and estimates for 2021 were calculated. ASR per 100,000 inhabitants was 5.14 (95% CI: 5.00-5.27) for myeloproliferative neoplasms (MPN), 4.71 (95% CI: 4.59-4.84) for myelodysplastic syndromes (MDS), 3.91 (95% CI: 3.79-4.02) for acute myeloid leukemia, 0.83 (95% CI: 0.78-0.88) for MDS/MPN, 0.35 (95% CI: 0.32-0.39) for acute leukemia of ambiguous lineage, and 0.58 (95% CI: 0.53-0.62) for not-otherwise specified (NOS) cases. This study highlights some useful points for public health authorities, such as the remarkable variability in incidence rates among Spanish provinces, the increasing incidence of MPN, MDS, and MDS/MPN during the period of study, in contrast to a drop in NOS cases, and the number of cases expected in 2021 based on these data (8446 new MNs).
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Differences in the impact of covid-19 on pathology laboratories and cancer diagnosis in girona

  • Sanvisens, Arantza|||0000-0001-6269-5491
  • Puigdemont, Montse|||0000-0001-9961-3699
  • Rubió-Casadevall, Jordi
  • Vidal Vila, Anna
  • López-Bonet, Eugeni
  • Martín-Romero, Ferran
  • Marcos-Gragera, Rafael|||0000-0001-9824-3657
Introduction: The recent COVID-19 pandemic has compromised socio-health care, with consequences for the diagnosis and follow-up of other pathologies. The aim of this study was to evaluate the impact of COVID-19 on cancer diagnosis in Girona, Spain. Methodology: Observational study of samples received in two pathology laboratories during 2019-2020 (tertiary hospital in Girona and county hospital in Figueres). Date, sample type, and location and morphology were available. Samples were recoded to determine malignancy and grouped by location. Comparisons were made by calendar year and period of exposure to COVID-19. Results: 102,360 samples were included: 80,517 from Girona and 21,843 from Figueres. The reduction in activity in the pathology laboratories in 2020 compared to the previous year was 25.4% in Girona and 27.5% in Figueres. The reduction in cancer diagnoses in 2020 compared to 2019 was 6.8% in Girona and 21% in Figueres. In both laboratories, a decrease was observed in the diagnoses of neoplasms of the lip, oral cavity and pharynx, larynx, colon, rectum and anus, kidney and urinary system, melanoma, and central nervous system. A statistically significant higher probability of a sample received in the pathology laboratory displaying malignancy during COVID-19 was found (Girona: OR = 1.28, 95% CI: 1.23-1.34; Figueres: OR = 1.10, 95% CI: 1.01-1.20) with respect to the COVID-19-free period. Conclusions: The COVID-19 pandemic has resulted in a reduction in cancer diagnoses by pathology departments that varies according to tumor location and type of hospital. Despite this, the optimization of care resources and the recovery effort have partially reduced the impact of the pandemic in certain neoplasms.